2A.02

Abstract

The aim of this study was to assess the efficacy of blood pressure (BP) control with fixed-dose combination of perindopril arginine/indapamide (Noliprel) in patients with uncontrolled hypertension.A total of 714 patients with uncontrolled hypertension from the PROTECT (noliPRel - efficacy of blood pressure cOnTrol on nEw diagnosed and unControlled patienTs) database, were included. At the beginning of the study the patients (mean age 64.9 ± 10.5 years; 223 men) were switched from antihypertensive drugs that had proven ineffective in BP control to Noliprel. BP was measured in the third and sixth months of the study. The primary end point was the number of patients reaching target BP levels in the intermediate phases of the study. The SPSS v.17.0 statistical software package was used for data collection and analysis. Results are presented as mean value ± standard deviation. Differences in mean values were analyzed using Student's paired-simple test.Mean systolic BP (SBP)/diastolic BP (DBP) declined significantly from 165.6 ± 14.4/96.8 ± 9.0 mmHg to 132.2 ± 10.7/80.1 ± 6.7 mmHg (p < 0.0001) over the course of the study. SBP/DBP reduction at three month was already -18.7 ± 14.2/-10.0 ± 9.6 mm Hg (p < 0.0001). Patients with BP values at target (<140/90 mmHg) represented 19.8% at 3 months, and 66.8% at 6 months. At the end of study, Noliprel was prescribed in 19.6% (perindopril arginine/indapamide 2.5 mg/0.625 mg), 61.8% (5 mg/1.25 mg), and 18.6% (10 mg/2.5 mg) of cases, respectively. No adverse effects were observed.The fixed-dose combination of perindopril arginine/indapamide was effective and safe in patients with uncontrolled hypertension in reducing BP and maintaining it at target levels.